The drugs, Atripla, Biktarvy, Descovy, Genvoya, Odefsey and Truvada, account for 95 percent of the revenue from Gilead’s HIV pipeline.
The price increases were significantly lower than previous hikes taken by Gilead and far below the the high-single digit price increases other companies have implemented, according to Tyler Van Buren, a senior biotech equity research analyst at Piper Jaffray.
Mr. Van Buren said that he believes the lower-than-usual price increases reflect the legislative push to lower drug prices, according to the report.
More articles on pharmacy:
Harvard gets $100M infusion for drug research from hedge fund
Purdue Pharma CEO: Bankruptcy is ‘an option’ amid lawsuits
Intermountain CEO Dr. Marc Harrison: How Civica Rx will disrupt the drug industry
